Feifei Tang

11PUBLICATIONS
23CO-AUTHORS
Haematological tumoursPredictive and prognostic markersBiomaterialsGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Mar 12, 2026
Co-Mutation of ASXL1 and KRAS Defines a Novel Ultra-Adverse-Risk Subtype of Acute Myeloid Leukemia in a Large-Scale Cohort.

Yijing Zhao, Ting Zhao, Feifei Tang

|Dec 01, 2025
Decoding the molecular drivers of TP53-mutant acute myeloid leukaemia: Clinical implications and prognostic insights.

Lin-Ya Wang, Hai-Tao Gao, Qiang Fu

|Aug 14, 2025
IKZF1 Variants Predicted Poor Outcomes in Acute Myeloid Leukemia Patients with CEBPA bZIP In-Frame Mutations.

Shunjie Yu, Lijuan Hu, Yazhen Qin

|Jul 12, 2025
KDM6A Variants Increased Relapse Risk in Adult Acute Myeloid Leukemia.

Yijing Zhao, Liting Niu, Sen Yang

|Feb 26, 2025
Clinical and Molecular Predictors of Response and Survival Following Venetoclax Plus Hypomethylating Agents in Relapsed/Refractory Acute Myeloid Leukemia: A Single-Center Study in Chinese Patients.

Linya Wang, Haitao Gao, Qiang Fu

|Apr 27, 2024
A complete oral regimen for induction therapy of patients with high-risk APL: An oral etoposide instead of intravenous infusion for cytoreductive chemotherapy.

Fei-Fei Tang, Wen-Bing Duan, Xiao-Hong Liu

Pageof 2

Frequent Collaborators

6 joint publications

Qian Jiang

4 joint publications

Yu Wang

4 joint publications

Xiaojun Huang

3 joint publications

Hao Jiang